- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02662738
The Effect of a Natural Extract on Glucose Fluxes After Consumption of a Wheat Product
October 25, 2016 updated by: Unilever R&D
This study is to quantify the effect of a natural fruit extract added to a wheat product on the time needed to absorb 50% of the apparent total of available exogenous carbohydrate (RaE * Time).
In addition the different glucose fluxes will be quantified (RaE, EGP and GCR)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hanzeplein 1
-
Groningen, Hanzeplein 1, Netherlands, 9713 GZ
- QPS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy Caucasian male.
- Body mass index (BMI) ≥ 18.0 and ≤ 25.0 kg/m2.
- Apparently healthy: no medical conditions which might affect the study measurements including diabetes type 1 and type 2, gastrointestinal dysfunction, gastrointestinal surgery and inflammatory diseases.
- Fasting blood glucose value of volunteer is ≥ 3.4 and ≤ 6.1 mmol/liter (i.e. 62- 110 mg/dl) at screening.
- HbA1c ≤ 6.5 % (48 mmol/mol).
Exclusion Criteria:
- Use of antibiotics within 3 months before Day 1; use of any other medication except paracetamol within 14 days before Day 1.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: A wheat product
A wheat product (containing 2% 13C-universally-labeled wheat) with natural fruit extract added.
|
|
|
Placebo Comparator: Control
A wheat product (containing 2% 13C-universally-labeled wheat) without natural fruit extract added.
|
|
|
Other: Glucose solution
A solution of 50g glucose of which 2% 13C-universally-labeled glucose (2%) and unlabeled glucose (98%) in 250 mL water.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
13C (13 carbon) and D-[6,6-2H2] glucose
Time Frame: 0-6 hours
|
0-6 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total blood glucose (BG)
Time Frame: 0-2 hours and 0-4 hours
|
0-2 hours and 0-4 hours
|
|
Insulin
Time Frame: 0-2 hours and 0-4 hours
|
0-2 hours and 0-4 hours
|
|
Endogenous glucose production (EGP)
Time Frame: 0-2 hours and 0-4 hours
|
0-2 hours and 0-4 hours
|
|
Glucose clearance rate (GCR)
Time Frame: 0-2 hours and 0-4 hours
|
0-2 hours and 0-4 hours
|
|
13C Metabolites of glucose (metabolomics)
Time Frame: 0-2 hours and 0-4 hours
|
0-2 hours and 0-4 hours
|
|
12C Metabolites of glucose (metabolomics)
Time Frame: 0-2 hours and 0-4 hours
|
0-2 hours and 0-4 hours
|
|
Postprandial hormones (Gastric inhibitory polypeptide, glucagon-like peptide-1 and Glucagon)
Time Frame: 0-2 hours and 0-4 hours
|
0-2 hours and 0-4 hours
|
|
Selected anti-oxidants (vitamin E (alpha-tocopherol), lycopene, retinol, alpha-carotene and beta-carotene)
Time Frame: -5, 60, 120, 180, 240 and 300 minutes
|
-5, 60, 120, 180, 240 and 300 minutes
|
|
Haematocrit
Time Frame: -5, 60, 120, 180, 240 and 300 minutes
|
-5, 60, 120, 180, 240 and 300 minutes
|
|
Concentration of key active in extract
Time Frame: -5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 and 360 minutes
|
-5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 and 360 minutes
|
|
13CO2 in breath
Time Frame: 30, 30, 60, 90,120, 150, 180 and every 30 minutes up to 6 hours
|
30, 30, 60, 90,120, 150, 180 and every 30 minutes up to 6 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Tjeerd Mensinga, MD, PhD, QPS Netherlands
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Actual)
February 1, 2016
Study Completion (Actual)
February 1, 2016
Study Registration Dates
First Submitted
January 20, 2016
First Submitted That Met QC Criteria
January 20, 2016
First Posted (Estimate)
January 25, 2016
Study Record Updates
Last Update Posted (Estimate)
October 26, 2016
Last Update Submitted That Met QC Criteria
October 25, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- FDS-NAA-1650
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.